drugset / Trial / NCT05023486
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
Multicenter, open-label study in patients with advanced or metastatic solid tumor malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK, and pharmacodynamics of continuously dosed NP-G2-044 monotherapy and NP-G2-044 in combination with anti-PD-1 therapy.
Timeline
- Start
- 2021-12-07
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NP-G2-044 | Small molecule | 1600 mg | Oral |
| Subject | NP-G2-044 | Small molecule | 2000 mg | Oral |
| Subject | NP-G2-044 | Small molecule | 2100 mg | Oral |
Indications
No indication recorded.